137 related articles for article (PubMed ID: 35439688)
1. Identification and optimisation of a pyrimidopyridone series of IRAK4 inhibitors.
Cumming IA; Degorce SL; Aagaard A; Braybrooke EL; Davies NL; Diène CR; Eatherton AJ; Felstead HR; Groombridge SD; Lenz EM; Li Y; Nai Y; Pearson S; Robb GR; Scott JS; Steward OR; Wu C; Xue Y; Zhang L; Zhang Y
Bioorg Med Chem; 2022 Jun; 63():116729. PubMed ID: 35439688
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88
Degorce SL; Anjum R; Bloecher A; Carbajo RJ; Dillman KS; Drew L; Halsall CT; Lenz EM; Lindsay NA; Mayo MF; Pink JH; Robb GR; Rosen A; Scott JS; Xue Y
J Med Chem; 2019 Nov; 62(21):9918-9930. PubMed ID: 31622099
[TBL] [Abstract][Full Text] [Related]
3. Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors.
Bhide RS; Keon A; Weigelt C; Sack JS; Schmidt RJ; Lin S; Xiao HY; Spergel SH; Kempson J; Pitts WJ; Carman J; Poss MA
Bioorg Med Chem Lett; 2017 Nov; 27(21):4908-4913. PubMed ID: 28947151
[TBL] [Abstract][Full Text] [Related]
4. Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.
Degorce SL; Anjum R; Dillman KS; Drew L; Groombridge SD; Halsall CT; Lenz EM; Lindsay NA; Mayo MF; Pink JH; Robb GR; Scott JS; Stokes S; Xue Y
Bioorg Med Chem; 2018 Feb; 26(4):913-924. PubMed ID: 29398441
[TBL] [Abstract][Full Text] [Related]
5. Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors.
Degorce SL; Aagaard A; Anjum R; Cumming IA; Diène CR; Fallan C; Johnson T; Leuchowius KJ; Orton AL; Pearson S; Robb GR; Rosen A; Scarfe GB; Scott JS; Smith JM; Steward OR; Terstiege I; Tucker MJ; Turner P; Wilkinson SD; Wrigley GL; Xue Y
Bioorg Med Chem; 2020 Dec; 28(23):115815. PubMed ID: 33091850
[TBL] [Abstract][Full Text] [Related]
6. Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase.
Cheney IW; Yan S; Appleby T; Walker H; Vo T; Yao N; Hamatake R; Hong Z; Wu JZ
Bioorg Med Chem Lett; 2007 Mar; 17(6):1679-83. PubMed ID: 17251021
[TBL] [Abstract][Full Text] [Related]
7. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4).
Wang L; Ferrao R; Li Q; Hatcher JM; Choi HG; Buhrlage SJ; Gray NS; Wu H
J Biol Chem; 2019 Mar; 294(12):4511-4519. PubMed ID: 30679311
[TBL] [Abstract][Full Text] [Related]
8. Efforts towards the optimization of a bi-aryl class of potent IRAK4 inhibitors.
Hanisak J; Seganish WM; McElroy WT; Tang H; Zhang R; Tsui HC; Fischmann T; Tulshian D; Tata J; Sondey C; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X
Bioorg Med Chem Lett; 2016 Sep; 26(17):4250-5. PubMed ID: 27476420
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of dihydrofuro[2,3-b]pyridine derivatives as potent IRAK4 inhibitors.
Hao Y; Ma J; Wang J; Yu X; Li Z; Wu S; Tian S; Ma H; He S; Zhang X
Eur J Med Chem; 2023 Oct; 258():115616. PubMed ID: 37413880
[TBL] [Abstract][Full Text] [Related]
10. Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.
Seganish WM; McElroy WT; Herr RJ; Brumfield S; Greenlee WJ; Harding J; Komanduri V; Matasi J; Prakash KC; Tulshian D; Yang J; Yet L; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X; Sondey C
Bioorg Med Chem Lett; 2015 Aug; 25(16):3203-7. PubMed ID: 26115573
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
Chen Y; Bai G; Ning Y; Cai S; Zhang T; Song P; Zhou J; Duan W; Ding J; Xie H; Zhang H
Eur J Med Chem; 2020 Mar; 190():112092. PubMed ID: 32014679
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, evaluation and optimization of potent IRAK4 inhibitors alleviating production of inflammatory cytokines in LPS-induced SIRS model.
Hao Y; Wang J; Ma J; Yu X; Li Z; Wu S; Tian S; Ma H; He S; Zhang X
Bioorg Chem; 2023 Aug; 137():106584. PubMed ID: 37163814
[TBL] [Abstract][Full Text] [Related]
13. Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4.
McElroy WT; Michael Seganish W; Jason Herr R; Harding J; Yang J; Yet L; Komanduri V; Prakash KC; Lavey B; Tulshian D; Greenlee WJ; Sondey C; Fischmann TO; Niu X
Bioorg Med Chem Lett; 2015 May; 25(9):1836-41. PubMed ID: 25870132
[TBL] [Abstract][Full Text] [Related]
14. Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation.
Zhang J; Fu L; Shen B; Liu Y; Wang W; Cai X; Kong L; Yan Y; Meng R; Zhang Z; Chen YP; Liu Q; Wan ZK; Zhou T; Wang X; Gavine P; Del Rosario A; Ahn K; Philippar U; Attar R; Yang J; Xu Y; Edwards JP; Dai X
Cell Chem Biol; 2020 Dec; 27(12):1500-1509.e13. PubMed ID: 32888499
[TBL] [Abstract][Full Text] [Related]
15. Non-peptidic inhibitors of human leukocyte elastase. 1. The design and synthesis of pyridone-containing inhibitors.
Warner P; Green RC; Gomes B; Strimpler AM
J Med Chem; 1994 Sep; 37(19):3090-9. PubMed ID: 7932532
[TBL] [Abstract][Full Text] [Related]
16. Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors.
Bryan MC; Drobnick J; Gobbi A; Kolesnikov A; Chen Y; Rajapaksa N; Ndubaku C; Feng J; Chang W; Francis R; Yu C; Choo EF; DeMent K; Ran Y; An L; Emson C; Huang Z; Sujatha-Bhaskar S; Brightbill H; DiPasquale A; Maher J; Wai J; McKenzie BS; Lupardus PJ; Zarrin AA; Kiefer JR
J Med Chem; 2019 Jul; 62(13):6223-6240. PubMed ID: 31082230
[TBL] [Abstract][Full Text] [Related]
17. Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
Scott JS; Degorce SL; Anjum R; Culshaw J; Davies RDM; Davies NL; Dillman KS; Dowling JE; Drew L; Ferguson AD; Groombridge SD; Halsall CT; Hudson JA; Lamont S; Lindsay NA; Marden SK; Mayo MF; Pease JE; Perkins DR; Pink JH; Robb GR; Rosen A; Shen M; McWhirter C; Wu D
J Med Chem; 2017 Dec; 60(24):10071-10091. PubMed ID: 29172502
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.
Lee KL; Ambler CM; Anderson DR; Boscoe BP; Bree AG; Brodfuehrer JI; Chang JS; Choi C; Chung S; Curran KJ; Day JE; Dehnhardt CM; Dower K; Drozda SE; Frisbie RK; Gavrin LK; Goldberg JA; Han S; Hegen M; Hepworth D; Hope HR; Kamtekar S; Kilty IC; Lee A; Lin LL; Lovering FE; Lowe MD; Mathias JP; Morgan HM; Murphy EA; Papaioannou N; Patny A; Pierce BS; Rao VR; Saiah E; Samardjiev IJ; Samas BM; Shen MWH; Shin JH; Soutter HH; Strohbach JW; Symanowicz PT; Thomason JR; Trzupek JD; Vargas R; Vincent F; Yan J; Zapf CW; Wright SW
J Med Chem; 2017 Jul; 60(13):5521-5542. PubMed ID: 28498658
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4.
Lim J; Altman MD; Baker J; Brubaker JD; Chen H; Chen Y; Fischmann T; Gibeau C; Kleinschek MA; Leccese E; Lesburg C; Maclean JK; Moy LY; Mulrooney EF; Presland J; Rakhilina L; Smith GF; Steinhuebel D; Yang R
ACS Med Chem Lett; 2015 Jun; 6(6):683-8. PubMed ID: 26101574
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and pharmacological evaluation of N-(3-carbamoyl-1H-pyrazol-4-yl)-1,3-oxazole-4-carboxamide derivatives as interleukin-1 receptor-associated kinase 4 inhibitors with reduced potential for cytochrome P450 1A2 induction.
Inami H; Mizutani T; Watanabe J; Hayashida H; Ito T; Terasawa T; Kontani T; Yamagishi H; Usuda H; Aoyama N; Imamura E; Ishikawa T
Bioorg Med Chem; 2023 May; 87():117302. PubMed ID: 37201454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
